New York, Feb 14, 2026, 18:09 EST — Closing bell’s rung. Market shut.
- Danaher shares slipped again, closing out the week with losses after falling for two straight sessions.
- U.S. markets are set to open again Tuesday, following the Presidents Day holiday closure.
- Traders are watching for the Fed minutes and major U.S. data, both potential catalysts to shake up rate expectations.
Danaher Corp dropped 1.1% to close at $212.58 on Friday, chalking up a second day in the red, even as the S&P 500 and Dow posted modest gains. The stock remains roughly 12% under its Jan. 22, 52-week high. Thermo Fisher declined as well; Abbott moved up, while Medtronic slipped.
This comes just before a shortened week—U.S. stock and bond markets are shuttered Monday for Presidents Day, with trading picking back up Tuesday, Feb. 17.
Risk appetite has wavered. The S&P 500 closed out Friday with a modest gain following softer U.S. inflation numbers, yet the major indexes just logged their sharpest weekly drop since November. Investors continue to juggle changing rate-cut expectations and another slide in tech stocks.
Danaher shares picked up speed to the downside a day early, tumbling 2.3% on Thursday as U.S. stocks turned lower and the stock’s four-day rally ended. Trading activity outpaced the 50-day average, according to MarketWatch data.
Danaher shares saw brisk action Friday, with roughly 5.29 million traded as prices bounced from $210.79 up to $218.75, historical data show.
Wall Street enters the week still searching for what’s going to move the needle. “It’s all this whack-a-mole game of trying to figure out what AI is going to destroy next,” said Art Hogan, chief market strategist at B Riley Wealth, speaking to Reuters in a Week Ahead column on Friday. Reuters
The Federal Reserve will release minutes from its Jan. 27-28 meeting this Wednesday, Feb. 18, at 2 p.m. ET, according to the central bank’s calendar.
The calendar gets busier two days on. The Bureau of Economic Analysis is set to drop its advance fourth-quarter GDP read and the Personal Income and Outlays report—including the PCE price index—Friday, Feb. 20 at 8:30 a.m. ET. Later that morning, at 10 a.m. ET, the University of Michigan’s final February consumer sentiment number is expected.
Danaher shareholders are watching to see if management’s upbeat late-January signals on demand can withstand the latest macro swings buffeting the market. CEO Rainer Blair had described a “strong finish to the year with better-than-expected performance across our portfolio,” highlighting gains in bioprocessing and a rebound in diagnostics and life sciences. Reuters
Danaher is pointing to a rebound in its end markets for 2026. The company, in its earnings report, projected low-single-digit growth for first-quarter “core revenue”—which excludes effects from currency, acquisitions, and divestitures—and laid out expectations for full-year core revenue growth between 3% and 6%. Danaher Corporation Investors
Still, there’s a lot that could trip things up here. A pullback in research budgets would slam lab tools and diagnostics stocks. Renewed weakness out of China? That’s another headwind. And if rate expectations tilt back toward “higher for longer,” higher-multiple names in healthcare and tools typically take the brunt.
Danaher and the broader sector are bracing for midweek catalysts: first up, the Fed minutes dropping Feb. 18. That’s just before the Feb. 20 wave of growth and PCE inflation data hits — numbers with enough heft to jolt the rate narrative.
